ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Collaborator: Procter and Gamble
• Treatments: Risedronate Sodium; Risedronic Acid

Criteria

Inclusion criteria :

• Postmenopausal ambulatory women

• Established osteoporosis

Exclusion criteria:

• History of cancer: basal cell or squamous cell carcinoma-documented 6-month remission,

• Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.